Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .
A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
BACKGROUND Although serotonin reuptake inhibitors ( SRIs ) are the most effective pharmacologic treatment currently available for patients with obsessive-compulsive disorder ( OCD ) , 40 % to 60 % of patients do not respond to this treatment . This study was conducted to evaluate the efficacy and tolerability of quetiapine in addition to an SRI for treatment-refractory patients with OCD . METHOD Forty patients ( 10 men/30 women , mean + /- SD age = 35.2 + /- 12.1 years ; range , 18 - 60 years ) with primary OCD according to DSM-IV criteria who were recruited between February 2001 and December 2002 were r and omly assigned in an 8-week , double-blind , placebo-controlled trial to receive dosages titrated upward to 300 mg/day of quetiapine ( N = 20 ) or placebo ( N = 20 ) in addition to their SRI treatment . At entry , all patients were unresponsive to courses of treatment with at least 2 different  SRIs  at a maximum tolerated dose for 8 weeks . During the study , primary efficacy was assessed according to change from baseline on the Yale-Brown Obsessive Compulsive Scale ( Y-BOCS ) . A responder was defined as having a final Clinical Global Impressions-Improvement scale rating of " very much improved " or " much improved " and a decrease of > or = 35 % in Y-BOCS score . RESULTS An intent-to-treat , last-observation-carried-forward analysis demonstrated a mean + /- SD decrease in Y-BOCS score of 9.0 + /- 7.0 ( 31 % ) in the quetiapine group and 1.8 + /- 3.4 ( 7 % ) in the placebo group ( F=16.99 , df=1,38 ; p < .001 ) . Eight ( 40 % ) of 20 patients in the quetiapine group and 2 ( 10 % ) of 20 patients in the placebo group were responders ( chi2=4.8 , df=1 , p=.028 ) . The most common side effects in the quetiapine group were somnolence , dry mouth , weight gain , and dizziness . CONCLUSION The results of this study show that quetiapine in addition to an SRI is beneficial for patients with OCD who do not respond to SRI treatment alone
Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .